Related by context. All words. (Click for frequent words.) 73 ganetespib 73 obatoclax 73 OXi# 72 PEG SN# 72 PXD# 72 nab paclitaxel 72 vascular disrupting agents 72 Tyrima 71 CBLC# 71 alvespimycin 71 docetaxel chemotherapy 71 TG# [003] 71 AEG# 71 Symadex 71 vascular disrupting agent 71 INCB# [001] 71 oral prodrug 71 HGS# 71 BAY #-# 71 anti leukemic 71 Sym# 71 Carfilzomib 71 fosbretabulin 71 pertuzumab 71 riociguat 70 pomalidomide 70 mapatumumab 70 angiogenesis inhibitor 70 Xanafide 70 CEQ# 70 Chemophase 70 mTOR inhibitors 70 pan HDAC inhibitor 70 EndoTAG TM -1 70 HGS ETR2 70 axitinib 70 tanespimycin 70 lenalidomide dexamethasone 70 Imprime PGG 70 MGd 70 xenograft models 70 CCX# 70 Proxinium TM 70 PRT# 70 seliciclib 70 ENMD # 70 sorafenib Nexavar 70 Aplidin 69 OMP #M# 69 Doxil ® 69 Panzem R NCD 69 HGS ETR1 69 enzastaurin 69 decitabine 69 phase IIb clinical 69 CIMZIA TM 69 TELCYTA 69 bevacizumab Avastin ® 69 mertansine 69 Amrubicin 69 preclinically 69 sunitinib malate 69 depsipeptide 69 pegylated liposomal doxorubicin 69 antiangiogenic 69 olaparib 69 Enzastaurin 69 vidofludimus 69 VAPRISOL 69 HSP# inhibitor 69 sapacitabine 69 Azedra 69 PSN# [002] 69 CR# vcMMAE 69 DACH platinum 69 estramustine 69 chemotherapeutic drug 69 BZL# 69 favorable pharmacokinetic profile 69 LY# [003] 68 Aflibercept 68 Phase Ib clinical 68 anti VEGF 68 APOPTONE 68 imetelstat 68 metaglidasen 68 Bezielle 68 HuMax EGFr 68 proteasome inhibitor 68 Omacetaxine 68 Archexin 68 adecatumumab 68 Bortezomib 68 Trastuzumab 68 SCH # 68 cediranib 68 GMX# 68 uric acid lowering 68 VA# [002] 68 GRN#L 68 Cloretazine R 68 romidepsin 68 microtubule targeting 68 ZYBRESTAT fosbretabulin 68 CYT# potent vascular disrupting 68 evaluating tivozanib 68 histone deacetylase inhibitor 68 glufosfamide 68 liposomal formulation 68 Romidepsin 68 TELINTRA 68 tyrosine kinase inhibitor 68 Traficet EN 68 YONDELIS 68 OHR/AVR# 68 zalutumumab 68 idarubicin 68 Seliciclib 68 neratinib 68 phase IIa clinical 68 IMC A# 68 brivaracetam 68 nucleoside analog 68 PSMA ADC 68 ELACYT 68 MEK inhibitors 68 multicenter Phase II 68 DFMO 68 Blinatumomab 68 PS# [001] 68 TLK# 67 investigational humanized monoclonal antibody 67 Aliskiren 67 HCV protease 67 IMA# 67 AMD# [003] 67 anti angiogenic agents 67 receptor tyrosine kinase inhibitor 67 Squalamine 67 mTOR inhibition 67 VEGF receptor 67 selective inhibition 67 Cloretazine 67 cilengitide 67 ALN TTR# 67 PKC# 67 Perifosine 67 JAK1 67 ISIS # 67 cMET 67 rNAPc2 67 HDACi 67 docetaxel Taxotere ® 67 indibulin 67 farletuzumab 67 Vandetanib 67 CYT# 67 anticancer therapies 67 TACI Ig 67 vorinostat 67 EOquin TM 67 CIMZIA ™ 67 Preclinical studies 67 lapatinib Tykerb 67 HuLuc# 67 elotuzumab 67 orally bioavailable 67 ATL# [001] 67 Aurora kinase 67 viral kinetics 67 Elotuzumab 67 GRN# 67 entinostat 67 Preclinical studies suggest 67 Fludara 67 ASONEP 67 docetaxel Taxotere R 67 bortezomib Velcade 67 antitumor effects 67 ixabepilone 67 molecularly targeted 67 Cloretazine R VNP#M 67 antithrombotic 67 REOLYSIN ® 67 Pemetrexed 67 liposomal doxorubicin 67 recurrent glioblastoma multiforme 67 EGFR HER2 67 Voreloxin 67 sorafenib tablets 67 IAP inhibitor 67 LEP ETU 67 Irinotecan 67 fibrotic disease 67 ISTODAX 67 TNFa 67 MAGE A3 ASCI 67 Panzem R 67 gemcitabine Gemzar 67 anti angiogenic therapy 67 chemoradiotherapy 67 INCB# [003] 67 VNP#M 67 histone deacetylase HDAC inhibitor 67 SUTENT 66 IL# PE#QQR 66 EndoTAGTM 1 66 orally administered inhibitor 66 relapsed ovarian cancer 66 CCR2 66 atacicept 66 BRAF inhibitor 66 deforolimus 66 ZYBRESTAT 66 huC# DM4 66 inhibitor RG# 66 CORT # 66 anti angiogenic 66 proteasome inhibitor bortezomib 66 alkylating agent 66 protein kinase inhibitor 66 Exherin TM 66 delafloxacin 66 Virulizin ® 66 JAK inhibitor 66 VEGF inhibitors 66 TRV# [001] 66 thalidomide Thalomid 66 imatinib Gleevec 66 novel anticancer 66 novel VDA molecule 66 Gleevec resistant 66 TTF Therapy 66 Panzem NCD 66 Vidaza azacitidine 66 adriamycin 66 teriflunomide 66 Akt activation 66 Fibrillex TM 66 trastuzumab Herceptin R 66 velafermin 66 dexpramipexole 66 Phase 2a trial 66 etoposide 66 Amigal 66 oxidative stress inducer 66 ZYBRESTAT TM 66 radiation sensitizer 66 antitumor 66 Golimumab 66 Microplasmin 66 overlapping toxicities 66 EVIZON 66 amrubicin 66 milatuzumab 66 talabostat 66 antiproliferative effects 66 PI3K/mTOR 66 luteinizing hormone releasing 66 relapsed multiple myeloma 66 acetonide FA 66 GAP #B# 66 huN# DM1 66 Glufosfamide 66 triphendiol 66 anticancer agent 66 taxane resistant 66 MEK inhibitor RDEA# 66 #ME# 66 Amplimexon 66 OncoVEX GM CSF 66 MOZOBIL 66 anti angiogenic agent 66 sorafenib Nexavar ® 66 Lixivaptan 66 CoFactor 66 Vidofludimus 66 omega interferon 66 plasma kallikrein inhibitor 66 EZN 66 AP# [003] 66 cytotoxic chemotherapy 66 JAK3 66 forodesine 66 CDK inhibitor 66 Phase Ib 66 antitumor activity 66 vinca alkaloid 66 targeted radiotherapeutic 66 DXL# 66 Aurora Kinase 66 Triapine R 66 phase Ib 66 preclinical efficacy 66 Phase Ib II 66 orally dosed 66 eniluracil 66 anticancer activity 66 capecitabine Xeloda R 66 ON #.Na 66 Targretin 66 Zybrestat 66 elesclomol 66 antibody MT# 66 RG# [001] 65 Phase Ib study 65 Angiolix 65 RLY# 65 MGCD# [001] 65 paclitaxel Taxol 65 BRIM2 65 MetMAb 65 pro angiogenic 65 MEK inhibitor 65 XmAb# 65 DAVANAT 65 SRT# [003] 65 TACE 65 Mipomersen 65 elacytarabine 65 Phase Ib clinical trials 65 phase IIb study 65 mecamylamine 65 Apoptone 65 pharmacodynamic properties 65 rindopepimut 65 Degarelix 65 AQ4N 65 systemically administered 65 factor Xa inhibitor 65 Phase #b/#a clinical 65 iSONEP 65 antitumor effect 65 Gefitinib 65 TRO# 65 urate lowering 65 Factor VIIa 65 HQK 65 erlotinib Tarceva ® 65 JAK2 inhibitor 65 DAPT 65 Reolysin 65 eculizumab 65 Abiraterone acetate 65 PD LID 65 proteasome inhibitors 65 oral antiviral 65 dasatinib Sprycel 65 PROCHYMAL 65 cannabinor 65 fenretinide 65 uricase 65 FOLOTYN ® 65 chemopreventive agent 65 immunomodulatory 65 ThermoDox R 65 vascular disrupting 65 FOLFOX6 chemotherapy regimen 65 platinum refractory 65 RhuDex ® 65 relapsed MM 65 IFN beta 65 Panzem 65 sunitinib 65 vandetanib 65 INTEGRILIN 65 CD# antibody [001] 65 Chrysalin 65 rFVIIa 65 IRX 2 65 neoadjuvant 65 Onconase 65 anti amnesic 65 Tarceva TM 65 Sapacitabine 65 small molecule tyrosine 65 PROMACTA 65 virus HCV protease inhibitor 65 fulvestrant 65 neuroprotectant 65 relapsed refractory multiple myeloma 65 Tasimelteon 65 rFIXFc 65 oral JAK1 65 immunomodulatory therapy 65 Ceplene/IL-2 65 urocortin 2 65 iroxanadine 65 tolvaptan 65 investigational monoclonal antibody 65 apremilast 65 carboplatin paclitaxel 65 immunostimulatory 65 AKT inhibitor 65 aflibercept 65 Ramoplanin 65 5 FU leucovorin 65 samalizumab 65 PI3K inhibitor 65 CINTREDEKIN BESUDOTOX 65 HGS ETR1 mapatumumab 65 XL# XL# XL# 65 investigational HCV polymerase 65 heavily pretreated 65 Dasatinib 65 antitumor efficacy 65 anticancer compound 65 targeting CD# 65 neurotrophic 65 TORISEL 65 Phase #b/#a 65 gefitinib Iressa 65 JAK inhibitors 65 SERMs 65 Pimavanserin 65 iniparib 65 potent antiproliferative 65 PRTX 65 interferon alfa 65 cisplatin chemotherapy 65 investigational therapies 65 systemic RNAi therapeutic 65 thymalfasin 65 administered subcutaneously 65 standard chemotherapy regimen 65 azacytidine 65 #D#C# 65 selective modulator 65 GW# [003] 65 Capesaris 65 Darusentan 65 cytostatic 65 INTEGRILIN R 65 selective kinase inhibitor 65 Vicinium TM 65 mTOR inhibitor 65 Afatinib 65 EGF receptor 65 MYDICAR ® 64 selective androgen receptor modulator 64 Pertuzumab 64 BNC# 64 epigenetic therapies 64 lumiliximab 64 imatinib therapy 64 tezampanel 64 placebo controlled clinical 64 Elocalcitol 64 novel peptide 64 Aplidin R 64 cangrelor 64 PEG PAL 64 eltrombopag 64 rBChE 64 Tamibarotene 64 APTIVUS r 64 CD# monoclonal antibody 64 Synavive 64 trial evaluating PRX# 64 cisplatin gemcitabine 64 adalimumab Humira 64 OvaRex R 64 Pralatrexate 64 Meets Primary Endpoint 64 ruxolitinib 64 posaconazole 64 PNP inhibitor 64 tubulin inhibitor 64 pharmacokinetic interactions 64 ARIKACE ™ 64 ocular formulation 64 motesanib 64 ProSavin 64 refractory gout 64 RDEA# 64 FOLFIRI 64 CRLX# 64 KRN# 64 ATL# [002] 64 EGFr 64 lenalidomide Revlimid R 64 RGB # 64 goserelin 64 HuMax CD4 64 anti fibrotic 64 Phase IIa trial 64 Tavocept 64 erythropoietic 64 multi kinase inhibitor 64 Talabostat 64 OMP #R# 64 paclitaxel Taxol ® 64 OncoVEX 64 antiangiogenic agent 64 bortezomib Velcade ® 64 nitazoxanide 64 pralatrexate 64 CCX# B 64 temozolomide 64 flavopiridol 64 Ophena TM 64 Cloretazine ® 64 refractory AML 64 tocilizumab 64 angiotensin receptor blocker ARB 64 Teriflunomide 64 sodium glucose cotransporter 64 Antitumor Activity 64 tesmilifene 64 antiangiogenesis 64 RNAi therapeutic targeting 64 GFT# 64 Atiprimod 64 Enzyme Replacement Therapy 64 SNT MC# 64 PDE4 inhibitor 64 Doxorubicin 64 pharmacodynamic effects 64 rituximab Rituxan 64 HRPC 64 PI3K inhibitors 64 Apixaban 64 velafermin belinostat 64 PEG Interferon lambda 64 Denufosol 64 antiangiogenic therapy 64 Phase #b/#a trial 64 Phase #/#a trial 64 somatostatin analogue 64 EGFR inhibitors 64 Phenoptin 64 ANG# 64 castrate resistant prostate cancer 64 ritonavir boosted 64 VEGF Trap 64 tramiprosate 64 EDEMA3 trial 64 Aclidinium 64 ZOLINZA 64 sunitinib Sutent 64 Factor Xa inhibitor 64 oral deforolimus 64 Xelox 64 selective antagonist 64 TriRima 64 tafamidis 64 GPIIb IIIa 64 cytoprotective 64 R roscovitine 64 MDV# 64 PLX# 64 CDDO Im 64 HER2 positive metastatic breast 64 tgAAC# 64 bleomycin 64 interferon IFN 64 STRIDE PD 64 telomerase inhibition 64 mycophenolate mofetil 64 CLORETAZINE TM VNP#M 64 combretastatin A4 phosphate CA4P 64 recurrent glioblastoma 64 topotecan 64 MGCD# [002] 64 direct thrombin inhibitors 64 AAG geldanamycin analog 64 isoform selective 64 fibrinolytic 64 Xcytrin 64 talactoferrin 64 bosutinib 64 ISF# 64 Dacogen decitabine 64 dose escalation 64 bosentan 64 EOquin 64 Capecitabine 64 pharmacokinetic PK 64 lomitapide 64 fluoropyrimidine 64 galiximab 64 Nexavar sorafenib 64 Deforolimus 64 ProLindac 64 Telintra 64 Trofex 64 Alocrest 64 MabCampath 64 ALA PDT 64 hedgehog pathway 64 immune modulatory 64 Asentar 64 Ozarelix 64 EGFR tyrosine kinase inhibitor 64 INT# [002] 64 IAP inhibitors 64 EXPAREL TM 64 HDAC inhibition 64 Interferon alpha 64 glucagon receptor 64 EGFR pathway 64 Serdaxin 64 NGX# 64 DU #b 64 gamma secretase inhibitor 64 Hsp# Inhibitor 64 cytokine refractory 64 Guanilib 64 IFN α 64 cobiprostone 64 celgosivir 64 JAK#/JAK# 64 DermaVir Patch 64 R#/MEM # 64 IMC #B 64 visilizumab 64 cortical stimulation 64 glioblastoma multiforme GBM 64 LHRH receptor positive 64 systemic antifungal 64 generation Hsp# inhibitor 64 pharmacodynamic profile 64 ZACTIMA 64 taxane chemotherapy 64 chemotherapeutic regimen 64 gemcitabine 64 antimetastatic 64 intravesical 64 custirsen 64 ESBA# 64 CTAP# Capsules 64 ara C 64 5FU 64 CYC# 64 pharmacodynamic PD 64 Cannabinor 64 LHRH antagonists 64 teduglutide 64 IMiDs R 64 Bicifadine 64 sitaxsentan 64 Tezampanel 64 Phase 2b trial 64 Phase IIa trials 64 CGEN # 64 CD# expressing 64 PEGylated Fab fragment 64 dosage regimens 64 EGFR expressing 64 DOXIL 64 Phase 1b trial 64 intravenous bisphosphonates 64 Randomized Phase 63 inhibitory effects 63 ALK inhibitor 63 tumor necrosis 63 Tarvacin TM 63 gemcitabine carboplatin 63 ELND# 63 BrachySil TM 63 RAV# 63 alagebrium 63 kinase inhibitor 63 BMS# 63 ATL/TV# 63 edifoligide 63 TNFalpha 63 dose escalation Phase 63 deacetylase inhibitors 63 budesonide foam 63 Bevacizumab 63 VDAs 63 chemotherapy induced neutropenia 63 Sudhir Agrawal D.Phil 63 demonstrated antitumor activity 63 Nanobody 63 nonclinical studies 63 pathophysiological effects 63 antidiabetic 63 dacetuzumab 63 temsirolimus 63 mu opioid receptor antagonist 63 FK# 63 AEGR 63 ONCONASE 63 mRCC 63 peg interferon 63 rHuPH# 63 Milatuzumab 63 histone deacetylase inhibitors 63 Neulasta ® 63 Linaclotide 63 otelixizumab 63 Nicole Onetto MD 63 cancer immunotherapies 63 corticosteroid dexamethasone 63 Methylnaltrexone 63 PRX# 63 midstage clinical 63 clevidipine 63 bendamustine 63 generation antisense inhibitor 63 calcitonin 63 LHRH agonists 63 KIACTA ™ 63 SAR# [004] 63 anti CD3 63 abiraterone acetate 63 Ceflatonin 63 Vorinostat 63 Cytoxan 63 antiangiogenic agents 63 Ostarine 63 THR beta agonist 63 Hsp# inhibitors 63 androgen independent 63 Laquinimod 63 PEP# [003] 63 midstage trials 63 lesinurad 63 Taxotere ® 63 ACZ# 63 cetuximab Erbitux ® 63 PEGylated interferon beta 1a 63 tipifarnib 63 SUTENT ® 63 Viprinex 63 HDAC Inhibitor 63 potent anticancer 63 Litx 63 XL# SAR# 63 metastatic hormone refractory 63 plasma kallikrein 63 dexrazoxane 63 AzaSite Plus 63 paclitaxel poliglumex 63 EGFR receptor 63 Vidaza ® 63 2 methoxyestradiol 63 Daclizumab 63 metastatic HRPC 63 PDX pralatrexate 63 Pivotal Phase 63 clodronate 63 Darinaparsin 63 Tß4 63 ACE inhibitor ramipril 63 platelet inhibitor 63 Gemcitabine 63 nucleoside analogs 63 CB2 selective receptor agonist 63 Resten NG 63 noninfectious uveitis 63 NP2 Enkephalin 63 octreotide 63 oral picoplatin 63 immune modulating 63 metastatic renal cell carcinoma 63 CG# [003] 63 PEGPH# 63 Annamycin 63 ACTEMRA TM 63 veltuzumab 63 cell lymphoma CTCL 63 S/GSK# 63 OMNARIS HFA 63 epithelial tumors 63 gemcitabine Gemzar ® 63 cardiac toxicity 63 colorectal liver metastases 63 afatinib 63 belinostat 63 trabedersen 63 Neuradiab 63 Pharmacokinetics PK 63 IMGN# 63 5 fluorouracil leucovorin 63 pain palliation 63 IL 1ß 63 pharmacodynamic endpoints 63 SYN# 63 confirmatory Phase III 63 signal transduction inhibitor 63 GAMMAGARD 63 REG1 63 INC# 63 metastatic castration resistant 63 olmesartan 63 sargramostim 63 nalbuphine ER 63 Hsp# inhibition 63 Copegus ribavirin 63 MMP inhibitors 63 Plicera 63 Adenoma Prevention 63 Vascugel 63 pharmacokinetic parameters 63 mGluR2 NAM 63 eprotirome 63 AMPK activators 63 Tumor Necrosis Factor 63 Dapagliflozin 63 double blinded placebo 63 ocrelizumab 63 MLN# 63 K ras mutations 63 PEGylated anti 63 PARP inhibitor 63 Anti VEGF 63 novel histone deacetylase 63 rilonacept 63 sclerostin 63 trastuzumab Herceptin 63 azacitidine 63 ARIKACE 63 Nexavar ® 63 Phase 2a clinical 63 limiting toxicity 63 Tanespimycin 63 OMAPRO 63 ibandronate 63 antiangiogenic activity 63 Amphinex ® 63 ELOXATIN 63 ancrod 63 Ocrelizumab 63 isoproterenol 63 chemotherapy docetaxel 63 Bevasiranib 63 Elesclomol 63 LT NS# 63 multikinase inhibitor 63 phosphate S1P 63 Phase 1b clinical trials 63 ongoing Phase 1b 63 lupus nephritis 63 multitargeted 63 HspE7 63 antiapoptotic 63 DDP# 63 gonadotropin releasing hormone GnRH 63 Triolex 63 superficial bladder cancer 63 preclinical studies 63 concurrent chemoradiation 63 SERCA2a 63 weekly subcutaneous injections 63 figitumumab 63 TNF α 63 ospemifene 63 LHRH 63 SinuNase 63 Revimmune 63 vinorelbine 63 apoptosis inducer 63 YONDELIS R 63 endostatin 63 HCV protease inhibitor 63 Tolvaptan 63 trastuzumab DM1 63 neoadjuvant treatment 63 HuMax CD# 63 induces apoptosis 63 trodusquemine 63 mitogen activated ERK kinase 63 GRNVAC1 63 teriparatide 63 Lu AA# 63 Actilon 63 xanthine oxidase inhibitor 63 D aspartate NMDA receptor 63 Anti angiogenic 63 bevacizumab Avastin 63 therapeutic monoclonal antibody 63 rhIL 7 63 Epratuzumab 63 dasatinib Sprycel ® 63 aflibercept VEGF Trap 63 TLR8 agonist 63 hour bronchodilation 63 metastatic RCC 63 compound AEZS 63 #I TM# 63 phase IIb trial 63 Rebif ® 63 varespladib 63 Cotara 63 Myocet 63 Abiraterone 63 Diffuse Large B 63 rALLy clinical trial 63 neointimal hyperplasia 63 subcutaneously administered 63 HCV protease inhibitors 63 Fludara ® 63 C1 INH 63 Androxal TM 63 Antiangiogenic 63 intravitreal injection 63 Azixa 63 castration resistant prostate cancer 63 Safinamide 63 vivo validation 63 maximally tolerated dose 63 Telbivudine 63 ADAGIO study 63 Elagolix 63 standard chemotherapy regimens 63 RSD# oral 63 taxane refractory 63 phase IIb 63 Hsp# inhibitor 63 REP# 63 picoplatin 63 ANAVEX #-# [001] 63 davunetide intranasal AL 63 solithromycin 63 imatinib resistant 63 colorectal cancer liver metastases 63 tolerability profiles 63 antisense inhibitors 63 radiolabeled monoclonal antibody 63 brostallicin 62 lorvotuzumab mertansine 62 Pharmacokinetic studies 62 PCK# 62 Lacosamide 62 epirubicin 62 chemokine receptor 62 EFAPROXYN 62 ponatinib 62 GLPG# 62 TYKERB 62 XL# inhibits 62 NATRECOR ® 62 Inosine 62 nilotinib 62 intracoronary 62 Phase 1b 62 Hepatocellular Carcinoma HCC 62 perifosine 62 Personalized Immunotherapy 62 p# inhibitor 62 Vaprisol 62 PREZISTA r 62 Cethromycin 62 VEGFR2 62 dacarbazine 62 Genz # 62 denileukin diftitox 62 NXL# 62 baminercept 62 CGRP 62 AT1R 62 6R BH4 62 Phase 2b Clinical Trial 62 exon skipping 62 TNF Tumor Necrosis Factor 62 menadione 62 ADAMTS# 62 oncolytic virus 62 IgG1 antibody 62 ularitide 62 locoregional disease 62 cetuximab Erbitux 62 methylnaltrexone 62 Exelixis XL# 62 Pivotal Phase III 62 pharmacokinetic PK study 62 MGN# 62 thromboembolic events 62 GRNCM1 62 canakinumab 62 TroVax ® 62 Viramidine 62 PTHrP 62 ribavirin RBV 62 registrational trial 62 Omacetaxine mepesuccinate 62 amikacin 62 pharmacodynamic 62 Phase 2b clinical 62 HCV NS5B polymerase 62 elvitegravir 62 factor Xa 62 antifibrotic 62 IGF 1R 62 DCCR 62 Vascular Wrap 62 LUX Lung 62 telaprevir dosed 62 refractory prostate cancer 62 trabectedin 62 RH1 62 KNS # 62 squalamine 62 panobinostat 62 Mitoxantrone 62 receptor inhibitor